Product Description
NUC-1031 (Acelarin), a phosphoramidate transformation of gemcitabine, was the first anti-cancer ProTide to enter the clinic. We find it displays important in vitro cytotoxicity differences to gemcitabine, and a genome-wide CRISPR/Cas9 genetic screening approach identified only the pyrimidine metabolism pathway as modifying cancer cell sensitivity to NUC-1031. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31113993/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: Fast Track - Biliary Tract Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nucana
Company Location: EDINBURGH X0 EH12 9DT
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Biliary Tract Cancer|Pancreatic Cancer|Adenocarcinoma|Acinar Cell Carcinoma|Gallbladder Cancer
Phase 2: Fallopian Tube Cancer|Ovarian Cancer
Phase 1: Biliary Tract Cancer|Liver Cancer|Cholangiocarcinoma|Gallbladder Cancer|Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2019-001025-28 | P3 |
Unknown status |
Adenocarcinoma|Gallbladder Cancer|Biliary Tract Cancer |
2023-06-06 |
|
| NuTide:121 | P3 |
Terminated |
Biliary Tract Cancer |
2022-03-02 |
|
| ACELARATE | P3 |
Suspended |
Pancreatic Cancer|Acinar Cell Carcinoma |
2020-09-01 |
|
| PRO-105 | P2 |
Terminated |
Ovarian Cancer |
2019-12-31 |